Valbiotis Revenue and Competitors
Estimated Revenue & Valuation
- Valbiotis's estimated annual revenue is currently $9.5M per year.
- Valbiotis's estimated revenue per employee is $155,000
Employee Data
- Valbiotis has 61 Employees.
- Valbiotis grew their employee count by 2% last year.
Valbiotis's People
| Name | Title | Email/Phone |
|---|
Valbiotis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Valbiotis?
Research & Development company committed to scientific innovation for preventing and fighting against metabolic diseases.
keywords:N/A
N/A
Total Funding
61
Number of Employees
$9.5M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Valbiotis News
2022-04-17 - Valbiotis Announces its Combined Shareholders General Meeting ...
Valbiotis (FR0013254851 ALVAL, PEA / PME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation...
2022-03-30 - Valbiotis Announces the Positive Results of Its Clinical Study on the ...
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular...
2022-03-22 - Valbiotis Announces Upcoming Organizational Changes of its Board ...
Recruitment of a new senior Chief Financial Officer to support the development of Valbiotis as a major player in health nutrition.
Other Companies in Périgny
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.7M | 84 | 14% | N/A |
#2 | $35.7M | 199 | 8% | N/A |
#3 | $63.6M | 214 | 27% | N/A |